Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL

Inclusion Criteria: 1. Age ≥18 years. 2. Histologically confirmed aggressive B-NHL. 3. Life expectancy \>3 months. 4. Appropriate organ function: Cardiac function: cardiac ejection fraction ≥50%; Liver function: alanine aminotransferase and glutamic aminotransferase ≤ 2 times the upper limit of normal values; renal function: serum creatinine clearance ≥80 mL/min; serum creatinine \<160 mmol/L Lung function: SPO2\>91% without oxygen intake 5. Adequate bone marrow reserve defined as: hemoglobin ≥90 g/L. platelet count ≥70 x 10\^9/L. absolute neutrophil count ≥1.5 x 10\^9/L. 6. The patient is capable of understanding and willing to provide written informed consent. 7. Subjects of childbearing or childbearing potential must be willing to practice birth control from the date of enrollment in this study until study follow-up. Exclusion Criteria: 1. severe hepatic and renal function abnormalities (alanine aminotransferase, bilirubin, creatinine \> 2 times the upper limit of normal); 2. Presence of organic heart disease with resulting clinical symptoms or abnormal cardiac function (NYHA cardiac function classification ≥ grade 2); 3. ECG QTc interval \>500 ms; 4. active hepatitis B/hepatitis C; 5. uncontrolled active infection; 6. human immunodeficiency virus infection; 7. concurrent other tumors requiring treatment or intervention; 8. current or anticipated need for systemic corticosteroid therapy; 9. pregnant or lactating women; 10. abandonment of consolidation autologous hematopoietic stem cell transplantation for financial reasons; 11. other psychological conditions that prevent the patient from participating in the study or signing the informed consent form; 12. Subjects who, in the judgment of the investigator, are unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or do not meet the requirements for participation in the study.